Engineering biology disrupts HIV drug manufacturing: systemic shift toward accessible, sustainable antiretrovirals

Indigenous medicinal systems in Africa and the Americas have long provided antiviral compounds, yet these are sidelined in favor of synthetic biotech solutions like Lenacapavir. The focus on engineered biology ignores the potential of ethnobotanical knowledge, which could reduce dependency on patented drugs and empower local communities. Additionally, indigenous concepts of health—such as the Māori *Te Whare Tapa Whā* model, which integrates spiritual, physical, and social well-being—offer frameworks for holistic HIV care that transcend Western biomedical reductionism.

The HIV epidemic is deeply entangled with colonial legacies, including the extraction of biological samples from African populations without consent (e.g., the 1990s AZT trials in Uganda) and the patenting of indigenous knowledge (e.g., the neem tree controversy). The current biotech approach mirrors historical patterns where Western science extracts value from the Global South while controlling access. The 1980s-'90s activism by groups like ACT UP and the Treatment Action Campaign (TAC) in South Africa laid the groundwork for today’s access struggles, yet their systemic critiques are rarely integrated into modern narratives.

In India, the *Ayurvedic* tradition classifies HIV as a *doshic* imbalance, leading to integrative treatments combining herbs, diet, and yoga in some clinics. Brazilian *saúde coletiva* (collective health) models prioritize community-based HIV prevention, contrasting with the individualistic Western pharmaceutical approach. Meanwhile, in Thailand, the *Baan Gerda* model—combining antiretroviral therapy with vocational training—has reduced stigma and improved adherence, offering a template for culturally resonant care. These systems highlight how HIV interventions succeed when they align with local values and social structures.

The MIB’s engineering biology approach leverages microbial fermentation to produce Lenacapavir at 90% lower cost and 80% reduced carbon footprint compared to traditional methods, aligning with WHO’s 2030 HIV elimination targets. However, the scientific narrative lacks critical examination of how *in vitro* success translates to real-world access, particularly in regions with fragile healthcare infrastructure. Peer-reviewed studies on the long-term ecological impacts of synthetic biology in drug manufacturing are also scarce, leaving potential unintended consequences unaddressed.

Artistic and spiritual responses to HIV—such as the *Names Project* AIDS Memorial Quilt or South African photographer Zanele Muholi’s work—frame the epidemic as a crisis of humanity, not just a medical challenge. Indigenous spiritual practices, such as the Māori *whakapapa* (genealogical) approach to health, emphasize interconnectedness, which could reshape HIV prevention messaging from fear-based to community-care models. Meanwhile, the global *Red* campaign’s use of art and celebrity to fundraise reflects a Western commodification of suffering, contrasting with grassroots movements that center lived experience.

If scaled, engineering biology could reduce HIV drug costs by 70-90% globally, but this hinges on breaking patent monopolies and investing in local production hubs in Africa and Latin America. Scenario modeling suggests that without parallel reforms in trade policy and healthcare infrastructure, even cheaper drugs will remain inaccessible to marginalized groups. Future-proofing requires integrating biotech with community health systems, as seen in Rwanda’s *Mutuelles de Santé* model, which combines insurance with local governance. The risk of biotech solutions being co-opted by corporate interests remains high without democratic oversight.

Sex workers, transgender women, and men who have sex with men—groups most affected by HIV—are systematically excluded from drug development narratives, despite bearing the brunt of the epidemic. In sub-Saharan Africa, women and girls account for 63% of new HIV infections, yet their priorities (e.g., reproductive autonomy, safety from gender-based violence) are rarely centered in treatment discussions. The omission of these voices reinforces a top-down approach where solutions are designed *for* marginalized communities rather than *by* them. Grassroots organizations like the *Global Network of People Living with HIV* (GNP+) have long demanded equitable access, but their demands are sidelined in favor of techno-optimistic narratives.